Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-Human Study of C106 in Healthy Subjects
NCT05427253Phase 1Completed
- Sponsor
- Vicore Pharma
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing C106 with Placebo (2 arms). Primary endpoints: Total Number of Treatment Emergent Adverse Events and Serious Adverse Events at Day 22, Number of Reported Clinically Significant Changes From Baseline in 12-lead Electrocardiograms at Day 22 and 3 more. Started Jun 2022; status: completed.
02
Drugs
C106
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05427253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427253.